A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

Authors

  • Jing Xu,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Zhong-Yang Shen,

    1. Orient Organ Transplant Center, Tianjin, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Xin-Guo Chen,

    1. Orient Organ Transplant Center, Tianjin, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Qing Zhang,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Hui-Jie Bian,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Ping Zhu,

    Corresponding author
    1. Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
    • Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, 17 West Changle Street, 710032, Xi'an, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Hui-Yun Xu,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
    • J. Xu, Z.-Y. Shen, X.-G. Chen, Q. Zhang, H.-J. Bian, P. Zhu, and H.-Y. Xu contributed equally to this work.

  • Fei Song,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Xiang-Min Yang,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Li Mi,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Qing-Chuan Zhao,

    1. Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Rong Tian,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Qiang Feng,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Si-He Zhang,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Yu Li,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Jian-Li Jiang,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Ling Li,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Xiao-Ling Yu,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Zheng Zhang,

    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    Search for more papers by this author
  • Zhi-Nan Chen

    Corresponding author
    1. Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China
    • Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, 17 West Changle Street, 710032, Xi'an, China
    Search for more papers by this author
    • fax: (86) 29-83226349


  • See Editorial on Page 263

  • Potential conflict of interest: Nothing to report.

Abstract

Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post-OLT antirecurrence efficacy of Licartin in advanced HCC patients. We randomized 60 post-OLT patients with HCC, who were at tumor stage 3/4 and outside the Milan criteria before OLT, into 2 groups. Three weeks after OLT, the treatment group received 15.4 MBq/kg of Licartin, while the control group received placebo intravenously for 3 times with an interval of 28 days. At 1-year follow-up, the recurrence rate significantly decreased by 30.4% (P = 0.0174) and the survival rate increased by 20.6% (P = 0.0289) in the treatment group, compared with those in the control group. For the control group versus the treatment group, the hazard ratio for recurrence was 3.60 (95% confidence interval [CI], 1.50-8.60) and that for death was 3.87 (95% CI, 1.23–12.21). Licartin treatment also resulted in an earlier decreased AFP level and a longer time of normal AFP level than placebo (P = 0.0016). No Licartin-related toxic effects were observed. Conclusion: Licartin is a promising drug for preventing post-OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. HAb18G/CD147 can be a good drug target. (HEPATOLOGY 2007;45:269–276.)

Ancillary